COMMUNIQUÉS West-GlobeNewswire

SERB Pharmaceuticals acquiert auprès de Hansa Biopharma les droits européens et MENA d’Idefirix® (imlifidase) pour 115 millions d’euros
20/05/2026
BRUXELLES, 20 mai 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, ci-après « SERB », et Hansa Biopharma AB, ci-après « Hansa » (Nasdaq Stockholm : HNSA) annoncent la conclusion d’un accord portant sur l’acquisition, par [...]
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
20/05/2026
Collaboration underway with Prof. Allan Young and King’s College, London First time a Selective Endocannabinoid Reuptake Inhibitor (SERI) molecule is dosed in a patient population BASEL, Switzerland, May 20, 2026 (GLOBE [...]
IBA lance Rhodotron® LITE, un nouvel accélérateur à rayons X de faible puissance qui facilite l’accès à des solutions d’irradiation durables
20/05/2026
Louvain-la-Neuve, Belgique, le 20 mai 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et des solutions de faisceaux d’électrons et à rayons X pour l’ [...]
IBA launches Rhodotron® LITE, a new low‑power X‑ray accelerator expanding access to sustainable irradiation solutions
20/05/2026
Louvain-la-Neuve, Belgium, May 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, [...]
SlimTide Claims Evaluated: The Baking Soda Water Shot Gelatin Trick for Losing Weight Naturally by Slim Tide
20/05/2026
Chicory Root Inulin, Resistant Starch, and Akkermansia Muciniphila Probiotic Blend for Gut Microbiome and Metabolic Support Explained Largo, FL, May 19, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
Shiny Smile Veneers Claims Evaluated (2026 Consumer Report Update) Critical Complaints Investigated
20/05/2026
Dr. Dean's Dentist-Designed Custom Snap-On Veneers: At-Home Impressions, FDA-Approved Biocompatible Resin, 3-Year Warranty, and 60-Day Money-Back Guarantee Richardson, TX , May 19, 2026 (GLOBE NEWSWIRE) -- Results may [...]
Java Tide Critical Assessment: The Gelatin Ice Trick Before Bed Using the Java Tide Formula Recipe
20/05/2026
Java Tide Scam or Legit, Complaints, Side Effects, and Supplement Ingredients: Chicory Root Inulin, Resistant Starch, Akkermansia muciniphila, and Gut Support Largo, FL, May 19, 2026 (GLOBE NEWSWIRE) -- These statements [...]
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
19/05/2026
IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening parasitic [...]
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
19/05/2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling [...]
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
19/05/2026
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition
19/05/2026
SPF-Infused Concealer Featuring Kleair™ , WHSPR™ , and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc . (Nasdaq: SLSN) a [...]
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
19/05/2026
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory [...]
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
19/05/2026
Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to [...]
Ozari Health Launches Nationwide Telehealth Platform for Compounded Semaglutide and Tirzepatide Starting at $86 Per Month
19/05/2026
LegitScript-verified platform connects patients with licensed providers for GLP-1 weight loss treatment, with transparent pricing, multiple pharmacy options, and no long-term contracts. New York, NY, May 19, 2026 (GLOBE [...]
Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur
19/05/2026
Essai de phase IV comparatif direct, en double aveugle, évaluant la tolérance et l’efficacité ayant atteint ses critères principaux et secondaires Les résultats de l’étude DIRECTION montrent que le profil de sécurité de [...]
Olema Oncology to Participate in Upcoming Investor Conferences
19/05/2026
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
19/05/2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, [...]
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
19/05/2026
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet [...]
Iridex Reports First Quarter 2026 Financial Results
19/05/2026
2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and [...]

Pages